Richard Arndt

612 total citations
17 papers, 351 citations indexed

About

Richard Arndt is a scholar working on Infectious Diseases, Neurology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Richard Arndt has authored 17 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 7 papers in Neurology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Richard Arndt's work include COVID-19 Clinical Research Studies (9 papers), SARS-CoV-2 and COVID-19 Research (8 papers) and Long-Term Effects of COVID-19 (6 papers). Richard Arndt is often cited by papers focused on COVID-19 Clinical Research Studies (9 papers), SARS-CoV-2 and COVID-19 Research (8 papers) and Long-Term Effects of COVID-19 (6 papers). Richard Arndt collaborates with scholars based in United States and Australia. Richard Arndt's co-authors include Raymund R. Razonable, Leigh L. Speicher, Sidna M. Tulledge‐Scheitel, Ravindra Ganesh, Sara N. Hanson, John C. O’Horo, Lori L. Arndt, Dennis M. Bierle, Caroline G. Wilker and Maria Teresa Seville and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Infectious Diseases and Mayo Clinic Proceedings.

In The Last Decade

Richard Arndt

17 papers receiving 343 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Arndt United States 8 242 109 50 49 34 17 351
Anna Rosenblatt United States 4 174 0.7× 100 0.9× 31 0.6× 57 1.2× 11 0.3× 6 252
Prabal Chourasia United States 9 119 0.5× 75 0.7× 42 0.8× 49 1.0× 5 0.1× 34 244
Karthik Gangu United States 9 94 0.4× 38 0.3× 45 0.9× 53 1.1× 8 0.2× 49 221
C K Ng China 5 218 0.9× 144 1.3× 57 1.1× 46 0.9× 4 0.1× 8 413
Viviane Cordeiro Veiga Brazil 8 76 0.3× 62 0.6× 49 1.0× 19 0.4× 11 0.3× 50 238
Kalyan Prudhvi United States 4 201 0.8× 52 0.5× 26 0.5× 14 0.3× 15 0.4× 10 296
Barun Babu Aryal United States 7 106 0.4× 46 0.4× 29 0.6× 11 0.2× 10 0.3× 28 222
Anela Kellogg United States 8 116 0.5× 34 0.3× 93 1.9× 30 0.6× 6 0.2× 8 264
Manuela Gerhold Germany 3 172 0.7× 83 0.8× 32 0.6× 11 0.2× 4 0.1× 3 263
Elena Aloisio Italy 10 100 0.4× 51 0.5× 76 1.5× 19 0.4× 5 0.1× 28 316

Countries citing papers authored by Richard Arndt

Since Specialization
Citations

This map shows the geographic impact of Richard Arndt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Arndt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Arndt more than expected).

Fields of papers citing papers by Richard Arndt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Arndt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Arndt. The network helps show where Richard Arndt may publish in the future.

Co-authorship network of co-authors of Richard Arndt

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Arndt. A scholar is included among the top collaborators of Richard Arndt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Arndt. Richard Arndt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Rivera, Christina G., Supavit Chesdachai, Richard Arndt, et al.. (2023). Clinical outcomes of COVID‐19 treated with remdesivir across the continuum of care. Influenza and Other Respiratory Viruses. 17(5). e13136–e13136. 4 indexed citations
2.
Chaudhry, Rajeev, et al.. (2023). Amiodarone Pharmacovigilance Through an Intelligent Electronic Health Record Application.. PubMed. 122(4). 280–283. 2 indexed citations
3.
Arndt, Richard, et al.. (2022). Impact of a perioperative pharmacist on completion rates for preoperative antibiotics. Perioperative Care and Operating Room Management. 29. 100290–100290. 1 indexed citations
4.
O’Horo, John C., Douglas W. Challener, Ryan J. Anderson, et al.. (2022). Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. Mayo Clinic Proceedings. 97(5). 943–950. 3 indexed citations
5.
Chaudhary, Rahul, Amteshwar Singh, Damon E. Houghton, et al.. (2022). Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage. JAMA Network Open. 5(11). e2240145–e2240145. 48 indexed citations
6.
Razonable, Raymund R., John C. O’Horo, Douglas W. Challener, et al.. (2022). Curbing the Delta Surge. Mayo Clinic Proceedings. 97(9). 1641–1648. 5 indexed citations
7.
Razonable, Raymund R., John C. O’Horo, Sara N. Hanson, et al.. (2022). Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch. The Journal of Infectious Diseases. 226(10). 1683–1687. 28 indexed citations
8.
Razonable, Raymund R., Sidna M. Tulledge‐Scheitel, Sara N. Hanson, et al.. (2022). Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch. Open Forum Infectious Diseases. 9(10). ofac411–ofac411. 19 indexed citations
9.
Razonable, Raymund R., Colin Pawlowski, John C. O’Horo, et al.. (2021). Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinicalMedicine. 40. 101102–101102. 97 indexed citations
10.
Ganesh, Ravindra, Colin Pawlowski, John C. O’Horo, et al.. (2021). Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. Journal of Clinical Investigation. 131(19). 36 indexed citations
11.
O’Horo, John C., Douglas W. Challener, Leigh L. Speicher, et al.. (2021). Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant. Mayo Clinic Proceedings. 97(2). 327–332. 16 indexed citations
12.
Razonable, Raymund R., Colin Pawlowski, John C. O’Horo, et al.. (2021). Casirivimab-Imdevimab Treatment Is Associated with Reduced Rates of Hospitalization Among High-Risk Patients with Mild to Moderate Coronavirus Disease-19. SSRN Electronic Journal. 6 indexed citations
13.
Wright, Jessica, et al.. (2021). Engagement of hospital pharmacists and technicians to optimize staffing schedules. Journal of Pharmaceutical Policy and Practice. 14(1). 70–70. 3 indexed citations
14.
Ganesh, Ravindra, Lindsey M. Philpot, Dennis M. Bierle, et al.. (2021). Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. The Journal of Infectious Diseases. 224(8). 1278–1286. 51 indexed citations
15.
Dexter, Donn, et al.. (2020). Effect of a Statewide Controlled-Substance Monitoring Requirement on the Opioid Prescribing Practice for Treatment of Acute Pain.. PubMed. 119(1). 33–36. 1 indexed citations
16.
Arndt, Richard, et al.. (2015). Pharmacist Impact on Ischemic Stroke Care in the Emergency Department. Journal of Emergency Medicine. 50(1). 187–193. 28 indexed citations
17.
Dorn, Spencer D., et al.. (2000). Falsely increased HbA1c values by HPLC and falsely decreased values by immunoassay lead to identification of Hb Okayama and help in the management of a diabetic patient.. PubMed. 46(11-12). 569–73. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Rosenblatt Breakdown of academic impact, for papers by Prabal Chourasia Breakdown of academic impact, for papers by Karthik Gangu Breakdown of academic impact, for papers by C K Ng Breakdown of academic impact, for papers by Viviane Cordeiro Veiga Breakdown of academic impact, for papers by Kalyan Prudhvi Breakdown of academic impact, for papers by Barun Babu Aryal Breakdown of academic impact, for papers by Anela Kellogg Breakdown of academic impact, for papers by Manuela Gerhold Breakdown of academic impact, for papers by Elena Aloisio
Rankless by CCL
2026